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Background: Recent advances in next-generation sequencing (NGS) have provided new methods for preimplantation
genetic screening (PGS) of human embryos from in vitro fertilization (IVF) cycles. However, there is still limited information
about clinical applications of NGS in IVF and PGS (IVF-PGS) treatments. The present study aimed to investigate the effects
of NGS screening on clinical pregnancy and implantation outcomes for PGS patients in comparison to array comparative
genomic hybridization (aCGH) screening.
Methods: This study was performed in two phases. Phase I study evaluated the accuracy of NGS for aneuploidy
screening in comparison to aCGH. Whole-genome amplification (WGA) products (n = 164) derived from previous IVF-PGS
cycles (n = 38) were retrospectively analyzed with NGS. The NGS results were then compared with those of aCGH. Phase
II study further compared clinical pregnancy and implantation outcomes between NGS and aCGH for IVF-PGS patients. A
total of 172 patients at mean age 35.2 ± 3.5 years were randomized into two groups: 1) NGS (Group A): patients (n = 86)
had embryos screened with NGS and 2) aCGH (Group B): patients (n = 86) had embryos screened with aCGH. For both
groups, blastocysts were vitrified after trophectoderm biopsy. One to two euploid blastocysts were thawed and
transferred to individual patients primarily based on the PGS results. Ongoing pregnancy and implantation rates were
compared between the two study groups.
Results: NGS detected all types of aneuploidies of human blastocysts accurately and provided a 100 % 24-chromosome
diagnosis consistency with the highly validated aCGH method. Moreover, NGS screening identified euploid blastocysts
for transfer and resulted in similarly high ongoing pregnancy rates for PGS patients compared to aCGH screening
(74.7 % vs. 69.2 %, respectively, p >0.05). The observed implantation rates were also comparable between the NGS and
aCGH groups (70.5 % vs. 66.2 %, respectively, p >0.05).
Conclusions: While NGS screening has been recently introduced to assist IVF patients, this is the first randomized clinical
study on the efficiency of NGS for preimplantation genetic screening in comparison to aCGH. With the observed high
accuracy of 24-chromosome diagnosis and the resulting high ongoing pregnancy and implantation rates, NGS has
demonstrated an efficient, robust high-throughput technology for PGS.
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Numerical chromosome abnormality or aneuploidy is
the main cause for embryo arrest, implantation failure,
recurrent pregnancy loss and birth defects [1–6]. Aneu-
ploidy rate is extremely high in IVF patients, especially
in those with recurrent pregnancy loss [4], repeated im-
plantation failure [5] and previous aneuploid concep-
tions [6]. Aneuploidy is the most common abnormality
in in-vitro fertilized zygotes and embryos [7–9], and
aneuploidy rate increases with maternal age [7–11]. Se-
lection of chromosomally normal embryos for transfer
by aneuploidy screening has been a primary focus of in-
vestigation since the inception of PGS [12, 13]. As the
field evolved, an increasing number of studies have
concentrated on developing more advanced technolo-
gies for screening embryos from IVF-PGS treatment cy-
cles in order to eliminate aneuploid embryos and to
select euploid embryos for transfer.
Fluorescence in situ hybridization (FISH) was the ori-
ginal method for aneuploidy screening of oocytes and
embryos from IVF treatment cycles [12–15]. In early PGS
studies, only a limited number (5–12) of chromosomes
were screened using FISH, which had an error rate of 5-
15 % and resulted in disappointing pregnancy outcomes
[16–19]. Conventional comparative genomic hybridization
(CGH) was then applied to screen all 24 chromosomes of
oocytes and embryos with some success, although it ty-
pically took several days to complete CGH testing [20].
Array comparative genomic hybridization has been re-
cently proven to be a reliable method for preimplantation
genetic screening within 24 h and has been widely applied
in IVF-PGS treatment cycles worldwide [21–31]. Mean-
while, single nucleotide polymorphism (SNP) array [32–35]
and qPCR-based comprehensive chromosomal screening
(CCS) [7, 36–39] have also been used for screening em-
bryos before transfer in order to improve the efficiency of
IVF and PGS treatments. More recently, next-generation
sequencing has been introduced into IVF field [40, 41].
With known advantages of robust high-throughput and
customizable parallel analysis of multiple samples in a
single sequencing run, several NGS platforms have been
validated and/or evaluated for preimplantation genetic
diagnosis (PGD) of specific mutations of nuclear [42] and
mitochondrial genomes [43], and preimplantation genetic
screening of chromosomal aberrations [43–46]. However,
there is still very limited information about efficiency of
NGS-based comprehensive chromosomal screening in
terms of clinical pregnancy and implantation outcomes for
IVF-PGS patients in a randomized study.
To date, there is no consensus on the best way to
screen embryos from IVF-PGS treatment cycles and to
select the most competent embryos for transfer despite
the recent advances in molecular cytogenetic technolo-
gies [40, 47]. Accordingly, our present study aimed atinvestigating the effects of NGS aneuploidy screening on
clinical pregnancy and implantation outcomes for IVF-
PGS patients in comparison to the highly validated
method of aneuploidy screening, aCGH.
Methods
Ethics statement
We obtained ethics approval for our study from the eth-
ics committees (also known as an Institutional Review
Board, IRB) at our respective institutions (e.g. ZytoGen's
IRB committee). All the participants had the capacity to
consent and we obtained the written informed consents
from all patients enrolled in the present study.
Study design and overview
This study was designated and performed in two phases.
Phase I study evaluated the accuracy of NGS for aneu-
ploidy screening across all 24 chromosomes in compari-
son to aCGH. A total of 164 whole-genome amplification
(WGA) products were selected from 38 IVF-PGS patients
at mean age 35.2 ± 3.4 years whose biopsy and aCGH were
performed previously [25, 48]. The PGS indications for
this group of patients included: 1) recurrent pregnancy
loss (n = 15), 2) repeated implantation failure (n = 13), and
3) previous aneuploidy conceptions (n = 10). These pa-
tients had their embryos screened with aCGH and transfer
of euploid blastocysts had resulted in ongoing pregnancies
and/or live birth of euploid babies as reported previously
[25, 48]. The selected WGA products were retrospectively
analyzed with NGS and the results were compared with
those of aCGH. The accuracy of NGS screening was eval-
uated by comparing with aCGH results from the overall
diagnosis of ploidy in individual blastocysts. In particular,
the sensitivity, specificity, positive and negative predictive
values of the NGS screening were calculated as described
by Fiorentino et al. [45].
Phase II study further compared the clinical pregnancy,
ongoing pregnancy and implantation outcomes between
NGS (Group A) and aCGH (Group B) for preimplantation
genetic screening through a prospective randomized de-
sign. PGS patients who met the inclusion criteria were
randomized into two groups by using a randomized table:
1) NGS (Group A), PGS patients (n = 86) had their em-
bryos screened with NGS and 2) aCGH (Group B), PGS
patients (n = 86) had their embryos screened with aCGH.
For both groups, all enrolled patients underwent oocyte
retrieval per routine and MII oocytes were fertilized by
intra cytoplasmic sperm injection (ICSI). All injected MII
oocytes were cultured to blastocyst stage in a time-lapse
system as described previously [48]. Blastocysts were vitri-
fied after trophectoderm biopsy. All WGA products of the
biopsy samples were analyzed with either NGS (Group A)
or aCGH (Group B). One to two euploid blastocysts were
thawed and transferred to individual patients primarily
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pregnancy and implantation rates were compared between
the two study groups.
Patient’s inclusion criteria and randomization
In Phase II study, a total of 172 patients at mean age
35.2 ± 3.5 years undergoing preimplantation genetic
screening were enrolled in this prospective, single-
blind, pilot interventional study in our multiple IVF
clinics in USA and China from July 2013 to June 2014.
A written informed consent was obtained from all pa-
tients and pre-treatment counseling was provided to
each couple. Standard clinical protocols and laboratory
procedures were used for the treatment of all patients
in this pilot study. The cohort patients requested PGS
due to recurrent pregnancy loss (n = 72), repeated im-
plantation failure (n = 63) and previous aneuploid con-
ceptions (n = 37). The inclusion criteria for enrollment
in this study were: 1) female patient’s age ≤ 39 years;
2) ≥ 4 blastocysts available for biopsy on day 5 (up to
11:00 pm); 3) presence of both ovaries and normal
uterine lining; 4) undergoing preimplantation genetic
screening for their embryos; and 5) willingness to par-
ticipate in the study and to follow instructions. The
exclusion criteria were: 1) patients whose treatment in-
corporated donor gametes; 2) patients with severe endo-
metriosis; 3) patients with endometrial factors related
infertility. A random number table generated by a com-
puter program was used to determine patients in PGS
method with either NGS (Group A) or aCGH (Group B).
Patients (but not the lab personnel) were blinded with re-
gard to their randomization groups. The two study groups
were mutually exclusive, and no study patient had em-
bryos assigned to both study groups.
The randomization table was generated using GraphPad
InStat version 3.10 (GraphPad Software, San Diego,
California, USA). A block randomization table was typ-
ically created for each of three groups with different clin-
ical indications: 1) recurrent pregnancy loss, 2) repeated
implantation failure and 3) previous aneuploid concep-
tions. Block randomization assured that parity of distribu-
tion was attained within each block for each clinical
indication. Based on the randomization table, a single sheet
of paper was prepared for each case indicating whether
that number was a Group A (NGS) patient or a Group B
(aCGH) patient. The number sheets were placed into
sealed envelopes with individual patient numbers. Once a
patient was qualified for the study, two lab personnel on
duty opened the envelopes and assigned the individual pa-
tients into Group A or Group B by following the assigned
number. Laboratory supervisors in charge confirmed the
assignment of randomization for individual patients in
each group. The following materials and methods, unless
specified, were applied to phase II study.Ovarian stimulation, oocyte retrieval and fertilization
All enrolled female patients had an ultrasound scan and
serum evaluation of follicle stimulation hormone (FSH),
anti Müllerian hormone (AMH) and estradiol (E2) on
day 3 of their menses. The patients were then stimulated
with conventional down-regulation protocols as de-
scribed previously [25, 48]. For female patients, oocyte
retrieval was performed under transvaginal ultrasound
guidance at 35 to 36 h after administration of hCG.
After stripping of cumulus cells, oocytes at MII stage
were inseminated with ICSI 4 h after retrieval as previ-
ously described [25, 48]. Fertilization was assessed 16–
18 h post ICSI. For male patients, sperm concentration
and motility were evaluated after 3 days of sexual abstin-
ence according to the World Health Organization
(WHO) recommendations [49].
Embryo culture and trophectoderm biopsy
For both study groups, all embryos were cultured from
one-cell to blastocyst stage in a continuous single culture
medium (CSC, Irvine Scientific, Irvine, USA) plus 12 %
synthetic serum substitute (SSS) within a time-lapse
system (EmbryoScope™, Unisense FertiliTech, Aarhus,
Denmark) at 37 °C, 6 % CO2, 5 % O2 as described previ-
ously [48]. When embryos developed to the blastocyst
stage on days 5 (up to 11:00 pm), an opening of 6 to 9 um
was made in the zona pellucida with several pulses of
18 ms from a non-contact 1.48 um diode Octax laser sys-
tem (MTG, Bruckberg, Germany), and 3 to 5 trophecto-
derm (TE) cells were aspirated into a biopsy pipette and
separated from the blastocysts by applying multiple laser
pulses of 14 ms between the trophectoderm cells at the
stretching area. The biopsied TE cells were washed in 1×
PBS and loaded into a PCR tube containing 2.5 μl 1× PBS.
All the biopsy and manipulation procedures were per-
formed in a fully enclosed workstation to provide a con-
trolled environment for manipulation of biopsied embryos
(Origio, Mt. Laurel, USA) as described previously [48].
aCGH testing
Whole genomic amplification (WGA) of the biopsy sam-
ples and aCGH testing in the aCGH group were per-
formed with the use of the Sureplex DNA Amplification
System (BlueGnome, Cambridge, UK) as reported else-
where [22, 25]. One nanogram of genomic DNA and
one reagent-negative control were also subjected to
WGA. The WGA products (sample and control DNA)
were labeled with Cy3 and Cy5 fluorophores for 2–4 h.
Labeled DNA was then resuspended in a dexsulphate
hybridization buffer and hybridized onto the 24sure
chips under cover slides for 4–6 h. After washing and
drying, the hybridized 24sure chips were scanned at
10 μm using a laser scanner (Agilent, Sainte Rosa, USA).
The scanning data were then analyzed and quantified by
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(BlueGnome, Cambridge, UK), a software package that
performed the steps of grid placement, quantification,
normalization and post-processing automatically. Once a
specific amplification was observed (i.e. low autosomal
noise), autosomal profiles were analyzed for gain or loss of
whole chromosomal ratios using a 3 × SD assessment,
greater than ± 0.3 log2 ratio call, or both according to the
manufacturer’s instructions (available at www.cytochip.-
com). To ensure hybridization quality controls, female
samples hybridized with a male reference DNA (sex mis-
match) had to show a consistent gain on chromosome X
and a consistent loss of chromosome Y [22].
Sequencing and sequence analysis
Whole genomic amplification of the biopsy samples in the
NGS group was performed using the same method as the
aCGH group. WGA products were then quantified using
the QuanTit dsDNA HS Assay Kit (Life Technologies Cor-
poration, Grand Island, NY, USA). Dual-indexed libraries
were prepared using the Nextera XT DNA Sample Prepar-
ation Kit and Index Kits with the input sample DNA at
0.2 ng/μl (1 ng total) (Illumina, San Diego, USA). The
quality of a subset of libraries was assessed using the Agi-
lent High Sensitivity DNA Kit (Agilent Technologies Inc,
Santa Clara, CA, USA) and by sequencing with the MiSeq
Reagent Kit v3 (Illumina Inc., San Diego, USA). Paired-
end, dual index 2x36bp sequencing was performed using
the Illumina workflow on a HiSeq 2000 with 96-plex per
lane (Illumina, San Diego, USA). Reads were aligned to
the human genome hg19 using iSAAC within the HiSeq
Analysis Software. Bash scripting, BEDtools and SAMtools
were used to remove unmapped reads, duplicate reads,
reads with low mapping scores and reads with an edit dis-
tance greater than one. Each chromosome was divided
into intervals each approximately covering 1 Mb of se-
quence. Filtered reads from each sample were then
mapped into the corresponding chromosome interval or
bin. The count data in each bin was normalized using GC
content, and in-silico reference data in order to remove
bias. The normalized bin counts were then re-expressed
as copy number by assuming the median autosomal read
count corresponds to copy number two. The bin-wise
copy number values for each chromosome were smoothed
with a 13-bin sliding median. Automated copy-number
status for each chromosome was determined using the
median of smoothed copy-number values across the
chromosome as described elsewhere [45]. In particular,
the analysis pipeline expected a default copy number of 2
for autosomes; the sample sex and sex chromosome copy
numbers were determined by an initial calling algorithm.
Embryos were diagnosed as abnormal or aneuploid if the
median chromosomal copy number measures deviated
from the default copy number. Chromosomal gain ortrisomy (copy number >2) and chromosomal loss or
monosomy (copy number <2) are seen as horizontal green
bars above and below, respectively in Figs. 1, 2 and 3, the
copy number state of 2. The method also allows a specific
copy number (1, 2, 3, or 4) to be directly assigned. Em-
bryos were diagnosed as normal or euploid if the gener-
ated plot showed no gain or loss.
Blastocyst vitrification and warming
After trophectoderm biopsy, blastocysts were vitrified using
the Cryotip method as previously described [26]. In brief,
blastocysts were equilibrated in equilibration solution (ES)
containing 7.5 % DMSO, 7.5 % ethyleneglycol and 20 %
SSS for 10–12 min. They were then passed through four
20 μl drops of virification solution (VS) containing 15 %
DMSO, 15 % ethyleneglycol, 0.5 M sucrose and 20 % SSS.
Individual blastocysts were loaded into the Cryotips within
90 s and plunged into liquid nitrogen immediately. For
warming, the Cryotip containing embryos was removed
from liquid nitrogen and thawed in a 37 °C water bath for
about 3 s and the contents were released as a small drop
in a culture dish. The Cryotip contents were then mixed
with the thawing solution (TS) containing 1.0 M sucrose,
20 % SSS in modified human tubal fluid (mHTF) for
1 min. The blastocysts were passed through two drops of
dilution solution (DS) containing 0.5 M sucrose, 20 % SSS.
They were then passed through two drops of washing so-
lution (WS) containing 20 % SSS in mHTF before placing
into blastocyst culture medium. After warming, one to
two euploid blastocysts were transferred to each patient
depending on individual patient’s age and indications, as
well as survival of the vitrified euploid blastocysts avail-
able. No more than two blastocysts were transferred to
each patient in order to avoid high-order multiple
pregnancies.
Embryo assessment and transfer
In both NGS and aCGH groups, fertilization was assessed
at 16 to 18 h post ICSI and the fertilized zygotes were then
cultured to blastocyst stage in the time-lapse system as de-
scribed previously [48]. Images of individual embryos were
captured with a built-in digital camera every 20 min at 7
different focal planes. Fertilization was assessed at 16 to
18 h post ICSI insemination according to the digital im-
ages acquired with the time-lapse monitoring system. De-
tailed analysis of the acquired images of each embryo was
made with the EmbryoView software (Unisense Fertli-
Tech, Denmark), and all the targeted events related to em-
bryonic development were then annotated together with
the corresponding hour(s) post ICSI insemination (hpi).
All morphokinetic data were recorded as mean ± SD hpi.
Selection of embryos for transfer was primarily based on
PGS results with NGS (Group A) or aCGH (Group B).
When multiple euploid blastocysts were recognized from
Fig. 1 Representative profiles showing different types of aneuploidies detected by NGS (the left panel) and aCGH (the right panel) screening of
the same whole genomic amplification (WGA) products. Each NGS profile in the left panel indicates the chromosome numbers on the x-axis and
copy numbers of chromosomes on the y-axis. Each aCGH profile in the right panal indicates the chromosome numbers on the x-axis and log
ratio of chromosomes on the y-axis. I. Aneuploid profile with single chromosomal gain (trisomy): a gain of chromosome 16; II. Aneuploid profile
with single chromosomal loss (monosomy): a loss of chromosome 13; III. Aneuploid profile with dual chromosomal abnormalities: a gain of
chromosomes 3 and a loss of 18; IV. Aneuploid profile with complex chromosomal abnormalities: gains of chromosomes 6 and 12 and losses of
chromosomes 9 and 15
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secondary criterion for selection according to the most
predictive parameters that were highly correlated with im-
plantation as described elsewhere [50, 51]. One to two eu-
ploid blastocysts within the most predictive parameters
available were selected for transfer to individual patients
after warming. For both study groups, patients were
treated using identical endometrial preparation protocols
as previously reported [26].
Sample size calculation and statistical analysis
Sample size in Phase II study was calculated using
GraphPad StatMate (GraphPad Software, San Diego,
California, USA). Based on our previous clinical studies
in which about 42 % of all transferred blastocysts im-
planted after transfer [25, 26, 48], a minimum sample
size of 110 blastocysts for transfer in each group had an
80 % power to detect a difference between means of 0.20with a significance level of 0.05 (two-tailed value). The
percentages of euploid and aneuploid blastocysts were
recorded and compared between NGS (Group A) and
aCGH (Group B). Clinical pregnancy, implantation and
ongoing pregnancy rates were also tabulated and com-
pared between the two study groups. Clinical pregnancy
was defined as an intrauterine gestational sac with fetal
heartbeat visualized by ultrasound examination at week
8 after embryo transfer. Ongoing pregnancy was defined
as continuing pregnancy at ≥ 20 weeks of gestation. Im-
plantation rate was calculated as the total number of
sacs with fetal hearts beat over the total embryos trans-
ferred. The categorical variables were analyzed by Chi-
square analysis or Fisher’s exact test as appropriate. The
numerical parameters were analyzed with t-test. The
time-lapse variables were first tested for normality using
the Shapiro-Wilk test and then analyzed by the Mann–
Whitney test. The statistical analyses were performed
Fig. 2 Representative profiles showing segmental imbalances detected by NGS (the upper profile) and aCGH (the lower profile) screening of the
same WGA product. The upper profile (a) was resulted from NGS screening which revealed a 42 Mb gain on the q arm of chromosome 16 and a
16 Mb loss on the q arm of chromosome 18 more precisely compared to aCGH screening in the lower profile (b)
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San Diego, USA). A two-tailed value of p <0.05 was con-
sidered statistically significant.
Results
Results from phase I study
A total of 164 WGA products derived from 38 IVF-PGS
treatment cycles were analyzed with NGS in comparison
to aCGH. The testing results from the same WGA prod-
ucts were compared between the two methods. A total
of 3936 (164 x 24) chromosomes from the biopsied blas-
tocysts (n = 164) were assessed for the entire copy num-
ber gains (copy number > 2) and losses (copy number <
2). NGS specificity for aneuploidy blastocyst call (all 24
chromosome diagnosis consistency) was 100 % (95 % CI:
95.32 %–100 %) with a sensitivity of a 100 % (95 % CI:
98.16 %–100 %). Both positive and negative predictive
values of the NGS screening were 100 % (Table 1).
NGS detected all types of aneuploidies including single
chromosome gain (or trisomy), single chromosome loss
(or monosomy), dual (two) and complex (three or more)
chromosomal abnormalities accurately compared to aCGH
(Fig. 1). NGS provided a 100 % 24-chromosome diagnosis
(of euploid and aneuploid) consistency with the highly vali-
dated method for aneuploidy screening, aCGH (Table 2).Detailed comparison of partial aneuploidies detected
by NGS and aCGH screening of the same WGA product
revealed that NGS detected partial chromosomal gains
and losses more precisely (Fig. 2), suggesting that NGS
may detect aneuploidy and segmental imbalances at the
same time. Further comparison of mosaicism detected
by NGS and aCGH screening of the same WGA product
revealed that NGS provided more accurate detection of
mosaicism of the trophectoderm cells from blastocyst bi-
opsy (Fig. 3).
Results from phase II study
As shown in Fig. 4, 257 patients were eligible for the
study entry and 85 of them were excluded from enroll-
ment due to personal reasons (n = 38), financial difficul-
ties (n = 26) or medical complications (n = 21). A total of
172 patients at mean age 35.2 ± 3.5 years (ranging from
28 to 39 years old) who met the inclusion criteria were
randomized into either NGS (Group A, n = 86) or aCGH
(Group B, n = 86). Of these, 3 patients in the NGS group
and 5 patients in the aCGH group withdrew from the
treatments for medical reasons. For Group A and Group
B, 83 and 81 patients completed the study and were in-
cluded in the final data analysis respectively. The demo-
graphic parameters of female and male patients were
Fig. 3 Representative profiles showing mosaicism resulted from NGS (the upper profile) and aCGH (the lower profile) screening of the same WGA
product. The upper profile (a) was resulted from NGS screening which revealed a 46 % mosaicism of chromosome 12 accurately. The lower
profile (b) was resulted from aCGH screening of the same WGA product, which was unable to detect the mosaicism of chromosome 12
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were no significant differences in female patient’s mean
age, day 3 FSH, AMH, E2, antral follicle number, male
patient’s sperm count and motility between the two
groups (p >0.05). As shown in Table 4, there were no
significant differences in fertilization rate (per MIITable 1 NGS technical assessment as compared to aCGH in
Phase I study
Parameters Results
Total number of blastocysts analyzed 164
Number of euploid blastocysts (true negative) 61
Number aneuploid blastocysts (true positive) 103
Number of missed aneuploid blastocyst call
(false negative)
0
Number of extra aneuploidy blastocyst call
(false positive)
0
Aneuploid blastocyst call specificity % (95 % CI) 100 % (95.32-100 %)
Aneuploid blastocyst call sensitivity % (95 % CI) 100 % (98.16-100 %)
Positive predictive value % (95 % CI) 100 % (97.43-100 %)
Negative predict value % (95 % CI) 100 % (95.25-100 %)
CI confidence interval, Specificity true negatives/(true negatives + false
positives), Sensitivity true positives/(true positives + false negatives), Positive
predictive value true positives/(true positives + false positives), Negative
predictive value true negatives / (false negatives + true negatives)oocytes) between Group A and Group B (89.8 % vs.
88.7 %, respectively, p >0.05). Moreover, the blastocyst
formation rate (per MII oocytes) in Group A was also
similar to that of Group B (48.9 % vs. 49.8 %, respect-
ively, p >0.05).
As summarized in Table 5, a total of 418 (93.5 %) blasto-
cysts in Group A were biopsied and analyzed by NGS. Bi-
opsies could not be completed for 29 (6.5 %) blastocysts
due to poor morphology or they degenerated after biopsy.
NGS analysis revealed euploidy in 163 (38.9 %) and aneu-
ploidy in 249 (59.6 %) of the biopsied blastocysts. No sig-
nals occurred in 6 (1.4 %) of the biopsied blastocysts due
to DNA amplification failure. In Group B, a total of 427
(94.5 %) blastocysts were biopsied while 25 (5.5 %) blasto-
cysts were not biopsied because of poor morphology or
they degenerated after biopsy. aCGH analysis revealed eu-
ploidy in 171 (40.0 %), aneuploidy in 247 (57.8 %) and no
signals in 9 (2.1 %) of the biopsied blastocysyts. Moreover,
chromosomal abnormalities were detected across all 24
chromosomes in both groups. As shown in Table 6, all
types of aneuploidies were observed in both Group A and
Group B, including trisomy, monosomy, dual and complex
chromosomal abnormalities. There were no significant dif-
ferences in the proportions of each type of aneuploidy be-
tween the two study groups (p >0.05).
Table 2 Comparison of percentages of different types of aneuplodies detected by NGS and aCGH screening of the same WGA
products in Phase I study
Parameters NGS aCGH p
Total number of WGA products analyzed 164 164
Euploid % (n) 37.2 % (61) 37.2 % (61) 1.000a
Aneuploid % (n) 62.8 % (103) 62.8 % (103) 1.000a
Monosomy % (n) 19.4 % (20) 19.4 % (20) 1.000a
Trisomy % (n) 16.5 % (17) 16.5 % (17) 1.000a
Dual chromosomal abnormality % (n) 24.3 % (25) 24.3 % (25) 1.000a
Complex chromosomal abnormality % (n) 35.9 % (37) 37.8 % (39) 0.885a
Mosaicism % (n) 2.5 % (4) 1.2 % (2) 0.683b
aby Chi-square analysis
bby Fisher’s exact test
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were highly correlated with implantation [50, 51] were
compared between the two study groups (Fig. 5). There
were no significant differences in the time from insemin-
ation to 5 cells (t5) between Group A and Group B
(50.2 ± 4.5 hpi vs. 50.4 ± 4.7 hpi, respectively, p >0.05).
The time between division to 2 cells and division to 3
cells (cc2) was similar in the two groups (11.3 ± 1.1 hpi
vs. 11.2 ± 1.2 hpi, respectively, p >0.05). Moreover, theFig. 4 Schematic for IVF-PGS patients randomized into either NGS (Group
red. The total number of blastocysts associated with each study group is citime between division to 3 cells and subsequent division
to 4 cells (s2) was also comparable between the two
study groups (0.78 ± 0.68 hpi vs. 0.77 ± 0.69 hpi, respect-
ively, p >0.05).
For both study groups, one to two euploid blastocysts
within the most predictive morphokinetic parameters
available were selected for transfer to individual patients.
As summarized in Table 7, a total of 79 (95.2 %) patients
had euploid blastocyst(s) for transfer while 4 (4.8 %) ofa) or aCGH (Group b). Excluded patients in each group were circled in
rcled in blue
Table 3 Comparison of patient’s demographic parameters between NGS (Group A) and aCGH (Group B) in Phase II study
Parameters NGS aCGH p
Total number of patients completed study 83 81
Mean female age ± SD 35.5 ± 3.3 35.2 ± 3.5 0.573
Mean D3 FSH (mUI/mL) ± SD 7.2 ± 1.6 7.1 ± 1.5 0.680
Mean AMH (ng/mL) ± SD 5.1 ± 2.1 4.6 ± 2.3 0.148
Mean E2 (pg/mL) ± SD 25.7 ± 3.2 26.3 ± 3.6 0.261
Mean antral follicles ± SD 12.3 ± 3.0 12.8 ± 2.8 0.272
Mean sperm count (million/mL) ± SD 35.4 ± 4.5 36.1 ± 4.2 0.305
Mean sperm motility (%) ± SD 49.6 ± 15.1 48.5 ± 14.7 0.637
There is no significant difference in any of the parameters between the two groups (p >0.05, by t test)
SD Standard deviation, NS No significant difference between the two groups, FSH Follicle stimulation hormone, AMH Anti-Müllerian hormone, E2 Estradiol
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fer in Group A. Among the patients with euploid blas-
tocysts for transfer, 27 patients had single euploid
blastocysts and 52 patients had double euploid blasto-
cysts for transfer. In Group B, a total of 78 (96.3 %) pa-
tients had euploid blastocysts for transfer while 3 (3.7 %)
of the patients ended with no euploid embryos available
for transfer. Of the patients with embryo transfer, 23 pa-
tients had single euploid blastocysts and 55 had double
euploid blastocysts for transfer. There was no significant
difference in clinical pregnancy rate between Group A
and Group B (75.9 % vs. 71.8 %, respectively, p >0.05).
The observed implantation rate in Group A was similar
to that of Group B (70.5 % vs. 66.2 %, respectively,
p >0.05). Ongoing pregnancy rate was also comparable
between Group A and Group B (74.7 % vs. 69.2 %, re-
spectively, p >0.05). Additionally, there was no signifi-
cant difference in miscarriage rate between NGS and
aCGH (1.3 % vs. 2.6 %, respectively, p >0.05).
Discussion
The ultimate goal of preimplantation genetic screening
of oocytes and embryos from in vitro fertilization treat-
ments is to select one to two chromosomally normal
embryos for transfer, so as to maximize the chances of
successful pregnancies and to minimize the incidences
of harmful miscarriages. As discussed previously, aneu-
ploidy rate is extremely high in IVF patients with recur-
rent pregnancy loss, repeated implantation failure andTable 4 Comparison of fertilization and blastocyst formation
rates between NGS (Group A) and aCGH (Group B) in Phase II
study
Parameters NGS aCGH p
Total number of oocytes retrieved 1063 1049
MII oocytes % (n) 85.9 % (914) 86.4 % (906) 0.847a
Oocytes fertilized (2PN) % (n) 89.8 % (821) 88.7 % (804) 0.502a
Blastocysts % (n) 48.9 % (447) 49.8 % (452) 0.709a
MII metaphase II, 2PN two pronuclei
aby Chi-square analysisprevious aneuploid conceptions [4–6]. Early randomized
clinical trials with FISH screening of a limited numbers
of chromosomes resulted in disappointing pregnancy
outcomes [16–19]. Recent studies with aCGH screening
of 24 chromosomes have resulted in a significant in-
crease in clinical and ongoing pregnancy rates for
patients either seeking single embryo transfer (SET)
[25, 26] or undergoing preimplantation genetic screening
[21–24, 27–31, 48]. More recent studies using cells of
known genetic complements and/or WGA products de-
rived from blastomere biopsy have indicated that NGS is
highly sensitive for aneuploidy screening [45], and trans-
fer of the screened embryos has resulted in viable preg-
nancies in several case studies [43, 44, 46]. In our
randomized pilot study, we provided further clinical evi-
dence demonstrating that NGS screening has resulted in
similarly high ongoing pregnancy and implantation rates
compared to aCGH screening. To date, this is the first
randomized clinical study on the efficiency of NGS-based
comprehensive chromosomal screening for IVF-PGS
patients in comparison to aCGH-based comprehensive
chromosomal screening.
In the present study, the accuracy and efficiency of
NGS screening of all 24 chromosomes were measured in
two phases. Phase I study evaluated accuracy of NGS
screening of WGA products selected from previously
performed IVF-PGS cycles in our IVF clinics. We chose
the NGS and aCGH platforms that were developed andTable 5 Comparison of biopsy and screening results between
NGS (Group A) and aCGH (Group B) in Phase II study
Parameters NGS aCGH p
Total number of blastocysts 447 452
Biopsied blastocysts % (n) 93.5 % (418) 94.5 % (427) 0.643a
Euploid % (n) 38.9 % (163) 40.0 % (171) 0.809a
Aneuploid % (n) 59.6 % (249) 57.8 % (247) 0.661a
No signal % (n) 1.4 % (6) 2.1 % (9) 0.604b
aby Chi-square analysis
bby Fisher’s exact test
Table 6 Comparison of screening results of each type of aneuploid blastocysts between NGS (Group A) and aCGH (Group B) in
Phase II study
Parameters NGS aCGH p
Total number of aneuploid blastocysts 249 247
Monosomy % (n) 21.7 % (54) 21.1 % (52) 0.950a
Trisomy % (n) 16.5 % (41) 17.8 % (44) 0.780a
Dual chromosomal abnormality % (n) 22.1 % (55) 23.1 % (57) 0.876a
Complex chromosomal abnormality % (n) 36.9 % (92) 36.8 % (91) 0.981a
Mosaicism % (n) 2.8 % (7) 1.2 % (3) 0.339b
aby Chi-square analysis
bby Fisher’s exact test
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Diego, USA) for strict comparison purposes. The aCGH
platform used in this study is the first technology that
has been widely adopted for aneuploidy screening across
all 24 chromosomes and has been extensively used in
IVF-PGS treatments worldwide [21–31]. The NGS plat-
form used in this study has been recently validated by
using cells of known abnormal genetic complements and
WGA products derived from blastomere biopsy of
cleavage-stage embryos [45]. The present study, using
trophectoderm cells from blastocyst biopsy, has provided
further clinical evidence showing that the NGS screening
accurately detected all types of aneuploidies of human
blastocysts compared to aCGH screening. Our current
data also confirmed previous observations [45, 46] that
NGS provided a 100 % 24-chromosome diagnosis con-
sistency with the highly validated aCGH method. In par-
ticular, all embryos (n =61) diagnosed as euploid by NGS
were proven to be euploid with aCGH and all embryosFig. 5 Comparison of morphokinetic parameters of the early stages of
embryonic development between NGS (red) and aCGH (blue) groups.
t2 = time from insemination to 2 cells; t3 = time from insemination to 3
cells; t5 = time from insemination to 5 cells; cc2 = time between division
to 2 cells and division to 3 cells; s2 = time between division to 3 cells
and subsequent division to 4 cells; hpi = hours post insemination.
Morphokinetic data were presented as mean ± SD. There were no
significant differences in each of the morphokinetic parameters
between NGS and aCGH groups (p >0.05, by Mann–Whitney test)(n =103) diagnosed as aneuploidy by NGS were con-
firmed as aneuploid by aCGH. Moreover, the NGS plat-
form presented here has also shown a capability of
detecting segmental changes more precisely compared
to aCGH, suggesting that the detection of partial aneu-
ploidies or imbalanced translocations is feasible with
the use of this NGS platform. Additionally, comparison
of mosaicism detected by NGS and aCGH screening of
the same WGA product revealed that NGS provided
more accurate detection of mosaicism compared to
aCGH.
There were additional advantages with use of NGS
screening compared to aCGH screening although the
current cost ($120 to $130 per sample) and the turn-
around time (18 to 20 h) for 24-chromosome screening
were similar between the two methods. With the use of
DNA barcoding technologies, NGS screening offers a
unique method for evaluation of multiple samples from
multiple patients with different indications, such as recur-
rent pregnancy loss, repeated implantation failure and pre-
vious aneuploid conceptions, on the same sequencing
chip. Up to 96 samples can be analyzed in a single run
with the use of an upgraded NGS instrument with high
capacity (e.g. Hiseq). In addition, NGS screening does not
require co-hybridization of DNA control samples while
aCGH testing requires both male and female DNA con-
trols in the hybridization step. With increasing volume of
PGS cases worldwide and improvement of platform pro-
duction on a larger scale, it is predictable that NGS
method may ultimately lead to lower costs per patient in
the near future.
Phase II study further compared the clinical pregnancy
and implantation outcomes between NGS (Group A) and
aCGH (Group B) for preimplantation genetic screening. A
large number (n = 172) of IVF-PGS patients who meet the
inclusion criteria were randomized into the two study
groups. Data analysis showed that the demographic pa-
rameters of both female and male patients in the two
study groups were similar (p >0.05). The fertilization and
blastocyst rates were also comparable between the two
study groups (p >0.05). The parallel comparison of the
Table 7 Comparison of pregnancy and implantation outcomes between NGS (Group A) and aCGH (Group B) in Phase II study
Parameters NGS aCGH p
Patients with SET 27 23
Patients with DET 52 55
Clinical pregnancy rate with SET % (n) 62.9 % (17) 60.9 % (14) 0.879a
Clinical pregnancies rate with DET % (n) 82.2 % (43) 76.4 % (42) 0.568a
Overall clinical pregnancy rate % (n) 75.9 % (60) 71.8 % (56) 0.681a
Overall implantation rate % (n) 70.5 % (92) 66.2 % (88) 0.564a
Overall ongoing pregnancy rate % (n) 74.7 % (59) 69.2 % (54) 0.560a
Overall miscarriage rate % (n) 1.3 % (1) 2.6 % (2) 0.620b
SET single embryo transfer, DET double embryo transfer
aby Chi-square analysis
bby Fisher’s exact test
Yang et al. BMC Medical Genomics  (2015) 8:30 Page 11 of 13results from transfer of the screened blastocysts revealed
that there were no significant differences in the clinical
pregnancy, ongoing pregnancy and implantation rates be-
tween NGS and aCGH groups (p >0.05). Collectively, our
pilot data clearly demonstrate that NGS is an efficient, ro-
bust technology for comprehensive chromosomal screen-
ing for IVF-PGS patients compared to the clinically
proven technology, aCGH. Recent studies with NGS
screening of embryos from several series of IVF cases at a
small scale have also resulted in viable pregnancies [43–46].
Our current data represent the first randomized clinical
study with a larger group of IVF-PGS patients to investigate
the effects of NGS screening on clinical pregnancy and im-
plantation outcomes in comparison to aCGH screening.
It is worth mentioning that all embryos in both Group
A and Group B throughout Phase II study were cultured
and monitored in the time-lapse system in order to
maximize the chances of a successful pregnancy. Our
previous study with sibling oocytes demonstrated that
the combination of time-lapse monitoring and aCGH
screening resulted in high clinical pregnancy and im-
plantation rates for IVF-PGS patients [48]. By using the
same approach, embryos in the present study were
screened with either NGS (Group A) or aCGH (Group
B) before transfer, and selection of euploid blastocyst(s)
for transfer was primarily based on PGS results for both
groups. When there were multiple euploid blastocysts
available for transfer in each patient, the most predictive
morphokinetic parameters were the secondary criterion
for embryo selection. Our present study has contributed
new clinical data demonstrating that the combination of
time-lapse monitoring and NGS screening has resulted
in similarly high clinical pregnancy, ongoing pregnancy
and implantation rates for PGS patients compared to the
combined use of time-lapse monitoring and aCGH
screening.
Several limitations of our pilot study should be ad-
dressed. First, although NGS-based comprehensive
chromosomal screening brings distinct benefits for manyIVF-PGS patients, the approach is not for all patients,
especially for those with diminished ovarian reserve. The
improved pregnancy rates achieved here may not be
fully applied to all IVF-PGS patients, especially those at
advanced maternal age of 40 years or above. Although it
is possible to accumulate enough blastocysts from mul-
tiple IVF treatment cycles by vitrification [52] before
NGS screening of the accumulated embryos from the
patients with diminished ovarian reserve or at advanced
maternal age, further randomized clinical trials with a
larger sample are required to confirm its clinical benefits
for these patients. Second, similar to other molecular
cytogenetic technologies, NGS is unable to detect bal-
anced chromosomal rearrangements directly due to lack
of imbalance in the total DNA content. Moreover, our
data showed that there was no significant difference in
mosaicism rate between NGS and aCGH groups (2.8 %
vs. 1.2 %, respectively, p >0.05). This may be due to in-
sufficient patient numbers in this category or limited
numbers of trophectoderm cells (3–5) being analyzed in
each biopsy sample. Finally, the WGA products in the
present study were not defined for unbalanced transloca-
tion breakpoints, although our current data was in
agreement with previous studies [45, 46] demonstrating
that NGS may detect chromosomal aneuploidy and im-
balanced derivatives at the same time. Hence, additional
studies with the use of cell lines or WGA products from
parents who carry known translocation breakpoints are
needed in order to assess the accuracy and limits of
NGS platforms, with high read depth and/or proper
coverage, for detection of imbalanced translocations.
Conclusion
In this randomized pilot study, we have demonstrated
that NGS detects all types of aneuploidies of human
blastocysts accurately and provides an extremely high
level of 24-chromosome diagnosis consistency with
aCGH. Moreover, NGS screening identifies euploid blas-
tocysts for transfer and results in similarly high ongoing
Yang et al. BMC Medical Genomics  (2015) 8:30 Page 12 of 13pregnancy and implantation rates for IVF-PGS patients
compared to aCGH screening. A multi-center random-
ized clinical trial with a larger sample is planned to de-
fine the role of NGS in assisted reproductive medicine.
Competing interests
ZY is the Scientific Director at ZytoGen Global Genetic Institute LLC. The
other authors declare that they have no competing interests.
Authors’ contributions
ZY and JL conceived and designed the study. ZY is the Scientific Director in
charge of ART and PGS programs. JL, JZ, WIF, PL, RZ, KY and JL are fertility
specialists in charge of the clinical programs. ZY wrote and edited the
manuscript. XL, WIF and WP are responsible for data mining and statistical
analysis. All authors read and approved the final manuscript.
Acknowledgments
The authors thank the clinical and laboratory staff at ZytoGen, Reproductive
Fertility Center, New Hope Fertility Center, Jia En DE Yun Hospital, Pacific
Reproductive Center, Hospital Conde S. Januário, Shanghai Ninth People’s
Hospital, Shanghai Jiao Tong University School of Medicine for their
assistance during this study. The authors deeply thank Dr. Claude-Edouard
Michel and Dr. Felix Kokocinski at Illumina for performing NGS testing.
Author details
1ZytoGen Global Genetics Institute, Timonium, MD, USA. 2Reproductive
Fertility Center, Irvine, CA, USA. 3New Hope Fertility Center, New York, NY,
USA. 4Hospital Conde S. Januário, Macau, P. R. China. 5Jia En De Yun Hospital,
Beijing, P. R. China. 6Pacific Reproductive Center, Torrance, CA, USA. 7Ninth
People’s Hospital, Shanghai Jiao Tong University School of Medicine,
Shanghai, P. R. China.
Received: 21 January 2015 Accepted: 16 June 2015
References
1. Alfarawati S, Fragouli E, Colls P, Stevens J, Gutierrez-Mateo C, Schoolcraft WB,
Katz-Jaffe MG, Wells D. The relationship between blastocyst morphology,
chromosomal abnormality, and embryo gender. Fertil Steril. 2011;95:520–4.
2. Hodes-Wertz B, Grifo J, Ghadir S, Kaplan B, Laskin CA, Glassner M, Munné S.
Idiopathic recurrent miscarriage is caused mostly by aneuploid embryos.
Fertil Steril. 2012;98:675–80.
3. Wilton L. Preimplantation genetic diagnosis and chromosome analysis of
blastomeres using comparative genomic hybridization. Hum Reprod
Update. 2005;11:33–41.
4. Rubio C, Simon C, Vidal F, Rodrigo L, Pehlivan T, Remohi J, Pellicer A.
Chromosomal abnormalities and embryo development in recurrent
miscarriage couples. Hum Reprod. 2003;18:182–8.
5. Voullaire L, Wilton L, McBain J, Callaghan T, Williamson R. Chromosome
abnormalities identified by comparative genomic hybridization in embryos
from women with repeated implantation failure. Mol Hum Reprod.
2002;8:1035–41.
6. Munné S, Sandalinas M, Magli C, Gianaroli L, Cohen J, Warburton D.
Increased rate of aneuploid embryos in young women with previous
aneuploid conceptions. Prenat Diagn. 2004;24:638–43.
7. Franasiak JM, Forman EJ, Hong KH, Werner MD, Upham KM, Treff NR, Scott
RT Jr. The nature of aneuploidy with increasing age of the female partner: a
review of 15,169 consecutive trophectoderm biopsies evaluated with
comprehensive chromosomal screening. Fert Steril. 2014;101:656–63.
8. Mantzouratou A, Delhanty JDA. Aneuploidy in the human cleavage stage
embryo. Cytogenet Genome Res. 2011;133:141–8.
9. Fragouli E, Wells D. Aneuploidy in the human blastocyst. Cytogenet
Genome Res. 2011;133:149–59.
10. Munné S, Alikani M, Tomkin G, Grifo J, Cohen J. Embryo morphology,
developmental rates, and maternal age are correlated with chromosome
abnormalities. Fertil Steril. 1995;64:382–91.
11. Hassold T, Hunt P. Maternal age and chromosomally abnormal pregnancies:
what we know and what we wish we knew. Curr Opin Pediatr.
2009;21:703–8.12. Delhanty JD, Griffin DK, Handyside AH, Harper J, Atkinson GH, Pieters MH,
Winston RM. Detection of aneuploidy and chromosomal mosaicism in
human embryos during preimplantation sex determination by fluorescent
in situ hybridization, (FISH). Hum Mol Genet. 1993;2:1183–5.
13. Munne S, Lee A, Rosenwaks Z, Grifo J, Cohen J. Diagnosis of major
chromosome aneuploidies in human preimplantation embryos.
Hum Reprod. 1993;8:2185–91.
14. Harper JC, Delhanty JD. Detection of chromosomal abnormalities in human
preimplantation embryos using FISH. J Assist Reprod Genet. 1996;13:137–9.
15. Gianaroli L, Magli MC, Ferraretti AP, Fiorentino A, Garrisi J, Munné S.
Preimplantation genetic diagnosis increases the implantation rate in human
in vitro fertilization by avoiding the transfer of chromosomally abnormal
embryos. Fertil Steril. 1997;68:1128–31.
16. Staessen C, Verpoest W, Donoso P, Haentjens P, Van der Elst J, Liebaers I,
Devroey P. Preimplantation genetic screening does not improve delivery
rate in women under the age of 36 following single-embryo transfer.
Hum Reprod. 2008;23:2818–25.
17. Hardarson T, Hanson C, Lundin K, Hillensjo T, Nilsson L, Stevic J, Reismer E,
Borg K, Wikland M, Bergh C. Preimplantation genetic screening in women
of advanced maternal age caused a decrease in clinical pregnancy rate: a
randomized controlled trial. Hum Reprod. 2008;23:2806–12.
18. Schoolcraft WB, Katz-Jaffe MG, Stevens J, Rawlins M, Munné S. Preimplantation
aneuploidy testing for infertile patients of advanced maternal age: a randomized
prospective trial. Fertil Steril. 2009;92:157–62.
19. Debrock S, Melotte C, Spiessens C, Peeraer K, Vanneste E, Meeuwis L,
Meuleman C, Frijns J-P, Vermeesch JR, D′Hooghe TM. Preimplantation genetic
screening for aneuploidy of embryos after in vitro fertilization in women aged
at least 35 years: a prospective randomized trial. Fertil Steril. 2010;93:364–73.
20. Wells D, Delhanty JD. Comprehensive chromosomal analysis of human
preimplantation embryos using whole genome amplification and single cell
comparative genomic hybridization. Mol Hum Reprod. 2000;6:1055–62.
21. Fishel S, Gordon A, Lynch C, Dowell K, Ndukwe G, Kelada E, Thornton S,
Jenner L, Cater E, Brown A, Garcia-Benardo J. Live birth after polar body
array comparative genomic hybridization prediction of embryo ploidy-the
future of IVF? Fertil Steril. 2010;93:1006e7–10.
22. Gutierrez-Mateo C, Colls P, Sanchez-Garcia J, Escudero T, Prates R, Ketterson K,
Wells D, Munné S. Validation of microarray comparative genomic hybridization
for comprehensive chromosome analysis of embryos. Fertil Steril. 2011;95:953–8.
23. Fiorentino F, Spizzichino L, Bono S, Biricik A, Kokkali G, Rienzi L, Ubaldi FM,
Iammarrone E, Gordon A, Pantos K. PGD for reciprocal and Robertsonian
translocations using array comparative genomic hybridization. Hum Reprod.
2011;26:1925–35.
24. Geraedts J, Montag M, Magli MC, Repping S, Handyside A, Staessen C,
Harper J, Schmutzler A, Collins J, Goossens V, van der Ven H, Vesela K,
Gianaroli L. Polar body array CGH for prediction of the status of the
corresponding oocyte. Part I: clinical results. Hum Reprod. 2011;26:3173–80.
25. Yang Z, Liu J, Collins GS, Salem SA, Liu X, Lyle SS, Peck AC, Sills ES, Salem
RD. Selection of single blastocysts for fresh transfer via standard
morphology assessment alone and with array CGH for good prognosis IVF
patients: results from a randomized pilot study. Mol Cytogenet. 2012;5:24.
26. Yang Z, Salem SA, Liu X, Kuang Y, Salem RD, Liu J. Selection of euploid
blastocysts for cryopreservation with array comparative genomic
hybridization (aCGH) results in increased implantation rates in subsequent
frozen and thawed embryo transfer cycles. Mol Cytogenet. 2013;6:32.
27. Capalbo A, Bono S, Spizzichino L, Biricik A, Baldi M, Colamaria S, Ubaldi FM,
Rienzi L, Fiorentino F. Sequential comprehensive chromosome analysis on
polar bodies, blastomeres and trophoblast: insights into female meiotic
errors and chromosomal segregation in the preimplantation window of
embryo development. Hum Reprod. 2013;28:509–18.
28. Rubio C, Rodrigo L, Mir P, Mateu E, Peinado V, Milán M, Al-Asmar N,
Campos-Galindo I, Garcia S, Simón C. Use of array comparative genomic
hybridization (array-CGH) for embryo assessment: clinical results. Fertil Steril.
2013;99:1044–8.
29. Harton GL, Munné S, Surrey M, Grifo J, Kaplan B, McCulloh DH, Griffin DK,
Wells D; PGD Practitioners Group. Diminished effect of maternal age on
implantation after preimplantation genetic diagnosis with array comparative
genomic hybridization. Fertil Steril. 2013;100:1695–703.
30. Greco E, Bono S, Ruberti A, Lobascio AM, Greco P, Biricik A, Spizzichino L,
Greco A, Tesarik J, Minasi MG, Fiorentino F. Comparative genomic hybridization
selection of blastocysts for repeated implantation failure treatment: a pilot
study. Biomed Res Int. 2014;2014:457913.
Yang et al. BMC Medical Genomics  (2015) 8:30 Page 13 of 1331. Rechitsky S, Pakhalchuk T, Ramos GS, Goodman A, Zlatopolsky Z, Kuliev A.
First systematic experience of preimplantation genetic diagnosis for
single-gene disorders, and/or preimplantation human leukocyte antigen
typing, combined with 24-chromosome aneuploidy testing. Fertil Steril.
2015;103:503–12.
32. Treff NR, Su J, Tao X, Levy B, Scott Jr RT. Accurate single cell 24
chromosome aneuploidy screening using whole genome amplification and
single nucleotide polymorphism microarrays. Fertil Steril. 2010;94:2017–21.
33. Johnson DS, Gemelos G, Baner J, Ryan A, Cinnioglu C, Banjevic M, Ross R,
Alper M, Barrett B, Frederick J, Potter D, Behr B, Rabinowitz M. Preclinical
validation of a microarray method for full molecular karyotyping of
blastomeres in a 24-h protocol. Hum Reprod. 2010;25:1066–75.
34. Lathi RB, Massie JAM, Gilani M, Milki AA, Westphal LM, Baker VL, Behr B.
Outcomes of trophectoderm biopsy on cryopreserved blastocysts: a case
series. Reprod Biomed Online. 2012;25:504–7.
35. Liu J, Wang W, Sun X, Liu L, Jin H, Li M, Witz C, Williams D, Griffith J,
Skorupski J, Haddad G, Gill J. DNA microarray reveals that high
proportions of human blastocysts from women of advanced maternal age
are aneuploid and mosaic. Biol Reprod. 2012;87:148.
36. Scott Jr RT, Ferry K, Su J, Tao X, Scott K, Treff NR. Comprehensive
chromosome screening is highly predictive of the reproductive potential of
human embryos: a prospective, blinded, nonselection study. Fertil Steril.
2012;97:870–5.
37. Treff NR, Tao X, Ferry KM, Su J, Taylor D, Scott Jr RT. Development and
validation of an accurate quantitative real-time polymerase chain reaction-
based assay for human blastocyst comprehensive chromosomal aneuploidy
screening. Fertil Steril. 2012;97:819–24.
38. Forman EJ, Tao X, Ferry KM, Taylor D, Treff NR, Scott Jr RT. Single embryo
transfer with comprehensive chromosome screening results in improved
ongoing pregnancy rates and decreased miscarriage rates. Hum Reprod.
2012;27:1217–22.
39. Scott Jr RT, Upham KM, Forman EJ, Hong KH, Scott KL, Taylor D, Tao X, Treff NR.
Blastocyst biopsy with comprehensive chromosome screening and fresh
embryo transfer significantly increases in vitro fertilization implantation and
delivery rates: a randomized controlled trial. Fertil Steril. 2013;100:697–703.
40. Handyside AH. 24-chromosome copy number analysis: a comparison of
available technologies. Fertl Steril. 2013;10:595–602.
41. Handyside AH, Wells D. Single nucleotide polymorphisms and next
generation sequencing. In: Gardner DK, Sakkas D, Seli E, Wells D, editors.
Human gametes and preimplantation embryos: assessment and diagnosis.
New York: Springer Science. Business Media; 2013. p. 135–46.
42. Treff NR, Fedick A, Tao X, Devkota B, Taylor D, Scott Jr RT. Evaluation of
targeted next-generation sequencing–based preimplantation genetic
diagnosis of monogenic disease. Fertil Steril. 2013;99:1377–84.
43. Wells D, Kaur K, Grifo J, Glassner M, Taylor JC, Fragouli E, Munné S. Clinical
utilisation of a rapid low-pass whole genome sequencing technique for the
diagnosis of aneuploidy in human embryos prior to implantation. J Med
Genet. 2014;51:553–62.
44. Yin X, Tan K, Vajta G, Jiang H, Tan Y, Zhang C, Chen F, Chen S, Sheng C,
Zhang C, Pan X, Gong C, Li X, C Lin, Gao Y, Liang Y, Yi X, Mu F, Zhao L,
Peng H, Xiong B, Zhang S, Cheng D, Lu G, Zhang X, Lin G, Wang W.
Massively parallel sequencing for chromosomal abnormality testing in
trophectoderm cells of human blastocysts. Biol Reprod. 2013;88:1–6.
45. Fiorentino F, Biricik A, Bono S, Spizzichino L, Cotroneo E, Cottone G,
Kokocinski F, Michel CE. Development and validation of a next-generation
sequencing–based protocol for 24 chromosome aneuploidy screening of
embryos. Fertil Steril. 2014;101:1376–82.
46. Fiorentino F, Bono S, Biricik A, Nuccitelli A, Cotroneo E, Cottone G,
Kokocinski F, Michel CE, Minasi MG, Greco E. Application of next-generation
sequencing technology for comprehensive aneuploidy screening of
blastocysts in clinical preimplantation genetic screening cycles.
Hum Reprod. 2014;9:2802–13.
47. Harper J, Geraedts J, Borry P, Cornel MC, Dondorp WJ, Gianaroli L, Harton G,
Milachich T, Kääriäinen H, Liebaers I, Morris M, Sequeiros J, Sermon K,
Shenfield F, Skirton H, Soini S, Spits C, Veiga A, Vermeesch JR, Viville S, de
Wert G, Macek M Jr. Current issues in medically assisted reproduction and
genetics in Europe: research, clinical practice, ethics, legal issues and policy.
Hum Reprod. 2014;29:1603–9.
48. Yang Z, Zhang J, Salem SA, Liu X, Kuang Y, Salem RD, Liu J. Selection of
competent blastocysts for transfer by combining time-lapse monitoring and
array CGH testing for patients undergoing preimplantation geneticscreening: a prospective study with sibling oocytes. BMC Med Genomics.
2014;7:38.
49. World Health Organization. WHO Laboratory Manual for the Examination
and Processing of Human Semen. 5th ed. Cambridge, UK: Cambridge.
University Press; 2010.
50. Meseguer M, Herrero J, Tejera A, Hilligsoe KM, Ramsing NB, Remohi J. The
use of morphokinetics as a predictor of embryo implantation. Hum Reprod.
2011;26:2658–71.
51. Meseguer M, Rubio I, Cruz M, Basile N, Marcos J, Requena A. Embryo
incubation and selection in a time-lapse monitoring system improves
pregnancy outcome compared with a standard incubator: a retrospective
cohort study. Fertil Steril. 2012;98:1481–9.
52. Kuang Y, Hong Q, Chen Q, Lyu Q, Ai A, Fu Y, Shoham Z. Luteal-phase
ovarian stimulation is feasible for producing competent oocytes in women
undergoing in vitro fertilization / intracytoplasmic sperm injection
treatment, with optimal pregnancy outcomes in frozen-thawed embryo
transfer cycles. Fertil Steril. 2014;101:105–11.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
